Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS

Neurology

Volumn 90, Issue 7, 2018, Pages e565-e574

  Benatar, Michael ^a   Wuu, Joanne ^a   Andersen, Peter M ^b   Atassi, Nazem ^c   David, William ^c   Cudkowicz, Merit ^c   Schoenfeld, David ^d,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c Department of Neurology ^*  (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIMOCLOMOL; COPPER ZINC SUPEROXIDE DISMUTASE; PLACEBO; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ANOREXIA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COMBINED ASSESSMENT OF FUNCTION AND SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIAPHORESIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; DYSPHAGIA; DYSPNEA; FALLING; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; HYPERSALIVATION; INFECTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN FOLDING; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; RESPIRATORY TRACT DISEASE; RESTLESSNESS; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

EID: 85048587347     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004960     Document Type: Article

References (27)

1. Ince PG, Tomkins J, Slade JY, Thatcher NM, Shaw PJ. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropathol Exp Neurol 1998;57:895-904.
2. Bergh J, Zetterstrom P, Andersen PM, et al. Structural and kinetic analysis of proteinaggregate strains in vivo using binary epitope mapping. Proc Natl Acad Sci USA 2015; 112:4489-4494.
3. Bidhendi EE, Bergh J, Zetterstrom P, Andersen PM, Marklund SL, Brannstrom T. Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis-like disease. J Clin Invest 2016;126:2249-2253.
4. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know Nat Rev Neurol 2011;7:603-615.
5. Hargitai J, Lewis H, Boros I, et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 2003;307:689-695.
6. Kalmar B, Burnstock G, Vrbova G, Urbanics R, Csermely P, Greensmith L. Upregulation of heat shock proteins rescues motoneurones from axotomy-induced cell death in neonatal rats. Exp Neurol 2002;176:87-97.
7. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-405.
8. Paul S, Mahanta S. Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door Mol Cell Biochem 2014; 386:45-61.
9. Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, Greensmith L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 2008;107:339-350.
10. Cudkowicz M, Shefner J, Simpson E, et al. Arimoclomol at dosages up to 300mg/day is well tolerated and safe in ALS. Muscle Nerve 2008;38:837-844.
11. Kim NH, Kim HJ, Kim M, Lee KW. A novel SOD1 gene mutation in a Korean family with amyotrophic lateral sclerosis. J Neurol Sci 2003;206:65-69.
12. Weber M, Neuwirth C, Thierbach J, et al. ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival. J Neurol Neurosurg Psychiatry 2012;83:351-353.
13. Lindberg MJ, Bystrom R, Boknas N, Andersen PM, Oliveberg M. Systematically perturbed folding patterns of amyotrophic lateral sclerosis (ALS)-associated SOD1 mutants. Proc Natl Acad Sci USA 2005;102:9754-9759.
14. Cudkowicz M, McKenna-Yasek D, Sapp P, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997;41:210-221.
15. Miano B, Stoddard GJ, Davis S, Bromberg MB. Inter-evaluator reliability of the ALS functional rating scale. Amyotroph Lateral Scler OtherMotor Neuron Disord 2004;5: 235-239.
16. Vandevoorde J, Verbanck S, Schuermans D, Kartounian J, Vincken W. FEV1/FEV6 and FEV6 as an alternative for FEV1/FVC and FVC in the spirometric detection of airway obstruction and restriction. Chest 2005;127:1560-1564.
17. Hankinson JL, Crapo RO, Jensen RL. Spirometric reference values for the 6-s FVC maneuver. Chest 2003;124:1805-1811.
18. Fisher LD. Self-designing clinical trials. Stat Med 1998;17:1551-1562.
19. Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler 2010;11: 178-180.
20. Cudkowicz M, Shefner J, Schoenfeld D, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-464.
21. Berry JD, Miller R, Moore DH, et al. The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:162-168.
22. Vonesh E, Greene T, Schluchter T. Shared parameter models for the joint rank analysis of longitudinal data and even times. Stat Med 2006;25:143-163.
23. Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719-1725.
24. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: A new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012; 33:176-182.
25. Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry 2016;88:99-105.
26. Lange DJ, Andersen PM, Remanan R, Marklund S, Benjamin D. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase I pilot study. Amyotroph Lateral Scler Frontotemporal Degener 2013;14: 199-204.
27. Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol 2013;12:435-442.